What are the dosing, administration, contraindications, and common adverse effects of Latuda (lurasidone) for treating schizophrenia and bipolar depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Latuda (Lurasidone) for Schizophrenia and Bipolar Depression

Latuda (lurasidone) is a second-generation antipsychotic approved for schizophrenia at 40-80 mg/day and bipolar I depression at 20-120 mg/day, taken once daily with food (≥350 calories), with a favorable metabolic profile but dose-dependent extrapyramidal symptoms and akathisia. 1

Dosing and Administration

Schizophrenia

  • Starting dose: 40 mg once daily (no titration required) 1
  • Therapeutic range: 40-80 mg/day 2, 3
  • Minimum effective dose: 40 mg/day 3
  • Maximum recommended dose: 160 mg/day (though 40-80 mg is the FDA-recommended range) 1

Bipolar I Depression

  • Dosing range: 20-120 mg/day 2
  • First-line status: Lurasidone is designated as a first-line treatment for acute bipolar depression 2
  • Optimal dose: 40-60 mg/day provides the best balance of efficacy and tolerability 4

Critical Administration Requirement

Must be taken with food containing ≥350 calories (absorption is reduced by 50% on an empty stomach) 1, 5. Fat content is not critical—total calorie content matters 6.

Contraindications

Absolute contraindications:

  • Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) 1, 7
  • Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) 1, 7

Relative contraindications/warnings:

  • Dementia-related psychosis (increased mortality risk—Black Box Warning) 1
  • Parkinson's disease or dementia with Lewy bodies (severe neurological adverse reactions) 1
  • Renal or hepatic impairment (requires dose adjustment) 1, 7

Common Adverse Effects

Most Common (≥5% and twice placebo rate)

In Schizophrenia: 1

  • Somnolence: 17% (vs 7% placebo)
  • Akathisia: 13% (vs 3% placebo)
  • Extrapyramidal symptoms: 14% (vs 6% placebo)
  • Nausea: 10% (vs 5% placebo)

In Bipolar Depression: 1

  • Akathisia
  • Extrapyramidal symptoms
  • Somnolence
  • Nausea, vomiting, diarrhea
  • Anxiety

Dose-Dependent Effects

Akathisia and extrapyramidal symptoms increase significantly with higher doses: 1

  • 20 mg: 5.6% akathisia, 5.6% EPS
  • 40 mg: 10.7% akathisia, 11.5% EPS
  • 80 mg: 12.3% akathisia, 11.9% EPS
  • 120 mg: 22.0% akathisia, 22.0% EPS

Metabolic Profile (Favorable)

Lurasidone has minimal metabolic effects compared to other atypical antipsychotics: 1, 5, 8

  • Weight gain: Minimal (0.38 kg at 40 mg) 4
  • Glucose: Slight increase only at doses >70 mg 4
  • Lipids: No clinically meaningful changes 9
  • QTc prolongation: Low risk 5, 9

Endocrine Effects

  • Hyperprolactinemia: Dose-dependent elevation (males: 3.21 ng/mL at 50 mg; females: 6.64 ng/mL at 50 mg), though prolactin-related adverse events are rarely reported 6, 4

Clinical Considerations

Mixed Features in Bipolar Depression

Lurasidone demonstrates benefits for treating mixed symptoms in bipolar depression 2, making it particularly useful when depressive episodes present with concurrent manic features.

Pharmacokinetics

  • Half-life: 18 ± 7 hours 5
  • Time to steady state: 5 days 5
  • Metabolism: Hepatic via CYP3A4 1, 7
  • Pregnancy category: B 7

Common Pitfalls

  1. Not taking with food: This is the most common error—absorption drops by 50% without adequate calories 5, 6
  2. Starting at too high a dose: Begin at 40 mg for schizophrenia; no titration needed 1
  3. Ignoring drug interactions: Always check for CYP3A4 inhibitors/inducers before prescribing 1, 7
  4. Overlooking akathisia: Monitor closely, especially at doses >80 mg; consider dose reduction or beta-blockers for management 1

Discontinuation Rate

Low discontinuation rates: 6-9.5% in clinical trials, comparable to placebo, indicating good overall tolerability 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.